Adjuvant treatment for endometrial cancer: Literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 231-240

  Morneau, Mélanie ^g,n   Foster, William ^e   Lalancette, Marc ^e   Van Nguyen Huynh, Thu ^j   Renaud, Marie Claude ^e   Samouëlian, Vanessa ^j   Letarte, Nathalie ^j   Almanric, Karine ^a   Boily, Gino ^b   Bouchard, Philippe ^c   Boulanger, Jim ^b   Cournoyer, Ghislain ^d   Couture, Félix ^e   Gervais, Normand ^f   Goulet, Stéphanie ^g   Guay, Marie Pascale ^h   Kavanagh, Mélanie ^g   Lemieux, Julie ^e   Lespérance, Bernard ⁱ   Ouellet, Jean François ^e   Pineau, Gilles ^b   Rajan, Raghu ^k   Roy, Isabelle ^a   Samson, Benoît ^l   Sidéris, Lucas ^c   Vincent, François ^m   more..

^a Hôpital Cité de la Santé et Direction de Santé Publique de Laval   (Canada)

^b Institut National D'excellence en Santé et en Services Sociaux   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d Hôpital Régional de Saint Jérôme CSSS de Saint Jérôme   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f Centre Hospitalier Régional du Grand Portage CSSS de Rivière du Loup   (Canada)

^g Direction Québécoise de Cancérologie MSSS   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^j NOTRE DAME HOSPITAL   (Canada)

^k MONTREAL GENERAL HOSPITAL   (Canada)

^l HÔPITAL CHARLES LEMOYNE   (Canada)

^m Greenfield Park ^*  (Canada)

ⁿ Centre intégré de santé et de services sociaux CISSS de Chaudière Appalaches   (Canada)

more..

Author keywords

Adjuvant; Cancer; Chemotherapy; Endometrium; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HYDROXYPROGESTERONE CAPROATE; IFOSFAMIDE; MEDROXYPROGESTERONE ACETATE; MESNA; OXYPROGESTERONE CAPROATE; PACLITAXEL; PIRARUBICIN; PROGESTERONE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANEMIA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CLINICAL OBSERVATION; COMORBIDITY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIAL CARCINOSARCOMA; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INCONTINENCE; LEUKOPENIA; META ANALYSIS (TOPIC); MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; URINARY URGENCY; UROGENITAL TRACT DISEASE; VAGINAL BRACHYTHERAPY;

EID: 84885307303     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.084     Document Type: Review

References (61)

1. Comité directeur de la Société canadienne du cancer. Statistiques canadiennes sur le cancer 2011. Toronto (Ontario): Société canadienne du cancer; 2012.
2. National Cancer Institute. SEER stats fact sheets: corpus and uterus, NOS. http://seer. cancer.gov/statfacts/html/corp.html; 2012 . [Consulted online on January 18, 2012].
3. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer, Int J Gynaecol Obstet 2006;95(suppl. 1):S105-43.
4. Galaal K, KewFM, TamKF, Lopes A,Meirovitz M, Naik R, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol 2009;143(2): 88-92.
5. Benedetti Panici P, Basile S,Maneschi F, Alberto LissoniA, SignorelliM, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100(23): 1707-16.
6. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373(9658): 125-36.
7. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;1:CD007585.
8. Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma - a prospective randomized study. Int J Radiat Oncol Biol Phys 2012;82(3): 1249-55.
9. Blake P, Swart AM, Orton J, Kitchener H,Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and metaanalysis. Lancet 2009;373(9658): 137-46.
10. KeysHM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(3): 744-51.
11. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213): 1404-11.
12. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 2001;51(5): 1246-55.
13. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003;89(2): 201-9.
14. Creutzberg CL, van PuttenWL,Warlam-Rodenhuis CC, van den Bergh AC, deWinter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22(7): 1234-41.
15. Scholten AN, van PuttenWL, Beerman H, Smit VT, Koper PC, Lybeert ML, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63(3): 834-8.
16. Nout RA, van de Poll-Franse LV, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treatedwith orwithout pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011;29(13): 1692-700.
17. Sorbe B, Nordstrom B, Maenpaa J, Kuhelj J, Kuhelj D, Okkan S, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009;19(5): 873-8.
18. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375(9717): 816-23.
19. Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27(21): 3547-56.
20. Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012;48(11): 1638-48.
21. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108(1): 226-33.
22. Maggi R, Lissoni A, Spina F,MelpignanoM, Zola P, FavalliG, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006;95(3): 266-71.
23. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24(1): 36-44.
24. Bruner DW, Barsevick A, Tian C, Randall M, Mannel R, Cohn DE, et al. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Qual Life Res 2007;16(1): 89-100.
25. Hogberg T, SignorelliM, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer 2010;46(13): 2422-31.
26. Kuoppala T, Maenpaa J, Tomas E, Puistola U, Salmi T, Grenman S, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008;110(2): 190-5.
27. Morrow CP, Bundy BN, Homesley HD, CreasmanWT, Hornback NB, Kurman R, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 1990;36(2): 166-71.
28. Fujimura H, Kikkawa F, Oguchi H, Nakashima N, Mizutani S. Adjuvant chemotherapy including cisplatin in endometrial carcinoma. Gynecol Obstet Invest 2000;50(2): 127-32.
29. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112(3): 543-52.
30. Cella D, Huang H, Homesley HD, Montag A, Salani R, De Geest K, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 2010;119(3): 538-42.
31. von Minckwitz G, Loibl S, Brunnert K, Kreienberg R, Melchert F, Mosch R, et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer - a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 2002;38(17): 2265-71.
32. COSA-NZ-UK Endometrial Cancer Groups. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 1998;8(5): 387-91.
33. De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 1993;29A(8): 1133-40.
34. Urbanski K, Karolewski K, Kojs Z, Klimek M, Dyba T. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 1993;14 suppl.: 98-104.
35. Vishnevsky AS, Bokhman Ya V, Loutfi G. Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen on 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients. Eur J Gynaecol Oncol 1993;14(2): 150-3.
36. Reed NS, Mangioni C,Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44(6): 808-18.
37. Wolfson AH, BradyMF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107(2): 177-85.
38. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114(11): 1313-20.
39. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012;3:CD003916.
40. Kong A, Johnson N, Cornes P, Simera I, Collingwood M, Williams C, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2007;2:CD003916.
41. Johnson N, Bryant A,Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011;10:CD003175.
42. Martin-Hirsch PP, Bryant A, Keep SL, Kitchener HC, Lilford R. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011;6:CD001040.
43. Martin-Hirsch PL, Lilford RJ, Jarvis GJ. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 1996;65(2): 201-7.
44. Lindemann K, Onsrud M, Kristensen G, Trope C. Survival after radiation therapy for early-stage endometrial carcinoma: the Oslo study revisited after up to 43 years of follow-up. J Clin Oncol 2012;30 (Suppl.): abstr 5008.
45. Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, et al. Late-breaking Abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2012;125(3):771.
46. Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15(3): 126-35.
47. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl. 6):vi35-9.
48. Noyes WR, Bastin K, Edwards SA, Buchler DA, Stitt JA, Thomadsen BR, et al. Postoperative vaginal cuff irradiation using high dose rate remote afterloading: a phase II clinical protocol. Int J Radiat Oncol Biol Phys 1995;32(5): 1439-43.
49. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels. Int J Radiat Oncol Biol Phys 2005;62(5): 1385-9.
50. Kong A, Simera I, Collingwood M, Williams C, Kitchener H. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 2007;18(10): 1595-604.
51. Aalders J, Abeler V, Kolstad P, OnsrudM. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56(4): 419-27.
52. Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol 1999;75(2): 211-4.
53. Patel S, Portelance L, Gilbert L, Tan L, Stanimir G, DuclosM, et al. Analysis of prognostic factors and patterns of recurrence in patientswith pathologic stage III endometrial cancer. Int J Radiat Oncol Biol Phys 2007;68(5): 1438-45.
54. Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller Jr AF. The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol Oncol 1996;63(1): 34-9.
55. Hoskins PJ, Swenerton KD, Pike JA,Wong F, Lim P, Acquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19(20): 4048-53.
56. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol 2011;22(3): 636-42.
57. Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008;18(4): 803-8.
58. Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P, Amant F. Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer 2009;19(6): 1147-51.
59. Kim HS, Kim JW, Wu HG, Chung HH, Park NH, Song YS, et al. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience. J Obstet Gynaecol Res 2010;36(3): 598-604.
60. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2011;1:CD006812.
61. Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992;102(4 Suppl.):305S-11S.